 HOLLISTON, Mass. , Aug. 4, 2022 PRNewswire -- Biostage, Inc. OTCQB: BSTG Biostage or the Company, a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer conducted at the Mayo Clinic and published last August and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that it will release Q2 2022 financial results on August 4, 2022 and host a conference call and webcast on August 5, 2022 at 9:00 AM ET to discuss financial results and business updates for the second-quarter 2022. 